On the contrary, the lack of a systematized evaluation of the impact of comorbidities and medication on GFAP values in ALS patients is one of the limitations, as the lack of neuropathological correlates of GFAP elevation in our cohort and the relatively low number of ALS patients with a full-blown AD co-pathology, partially due to the rarity of ALS itself. This evidence concerns the gene GFAP and amyotrophic lateral sclerosis.